Maia Bosca-Watts
Overview
Explore the profile of Maia Bosca-Watts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia M, Brenes Y, Vicuna M, Bermejo F, Sierra-Ausin M, Vicente R, et al.
Am J Gastroenterol
. 2024 Nov;
PMID: 39588977
Introduction: Real-world data on the effectiveness of upadacitinib for inflammatory bowel disease (IBD) are limited. To assess upadacitinib persistence, effectiveness, and safety in a real-world scenario. Methods: Retrospective multicenter study...
2.
DAmico F, Massimino L, Palmieri G, Dal Buono A, Gabbiadini R, Caron B, et al.
Eur J Clin Invest
. 2024 Jul;
54(11):e14283.
PMID: 38979834
Background And Aims: Subcutaneous (SC) formulations of infliximab (IFX) and vedolizumab (VDZ) are approved for the treatment of inflammatory bowel diseases (IBDs). Our aim was to evaluate the effectiveness of...
3.
Rodriguez-Lago I, Herrera-deGuise C, Bosca-Watts M, Rodriguez C, Leo-Carnerero E, Calvo Iniguez M, et al.
Gastroenterol Hepatol
. 2024 May;
47(10):502195.
PMID: 38710466
Objective: Granulocyte-monocyte apheresis (GMA) has shown to be safe and effective in ulcerative colitis (UC), also in combination with biologics, mainly with anti-TNF. The aim of this study was to...
4.
Rubin de Celix C, Martin-de-Carpi J, Pujol-Muncunill G, Palomino L, Rodriguez-Belvis M, Martin-Masot R, et al.
J Clin Med
. 2023 Jul;
12(14).
PMID: 37510928
(1) Background: Transition is a planned movement of paediatric patients to adult healthcare systems, and its implementation is not yet established in all inflammatory bowel disease (IBD) units. The aim...
5.
Chaparro M, Acosta D, Rodriguez C, Mesonero F, Vicuna M, Barreiro-de Acosta M, et al.
Am J Gastroenterol
. 2023 Jan;
118(7):1237-1247.
PMID: 36716287
Introduction: The objective of this study was to assess the durability, short-term and long-term effectiveness, and safety of tofacitinib in ulcerative colitis (UC) in clinical practice. Methods: This is a...
6.
Zabana Y, Marin-Jimenez I, Rodriguez-Lago I, Vera I, Martin-Arranz M, Guerra I, et al.
J Clin Med
. 2022 Dec;
11(24).
PMID: 36556155
(1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to...
7.
Manosa M, Fernandez-Clotet A, Nos P, Martin-Arranz M, Mancenido N, Carbajo A, et al.
Dig Liver Dis
. 2022 Aug;
55(1):46-52.
PMID: 35948459
Background: Anti-TNF agents are the only effective biological agents for the prevention of postoperative recurrence (POR) in Crohn's disease (CD). However, they are contraindicated or have been shown to fail...
8.
Gutierrez A, Zapater P, Ricart E, Gonzalez-Vivo M, Gordillo J, Olivares D, et al.
Front Med (Lausanne)
. 2022 Feb;
9:823900.
PMID: 35178413
Background: Previous studies comparing immigrant ethnic groups and native patients with IBD have yielded clinical and phenotypic differences. To date, no study has focused on the immigrant IBD population in...
9.
Zabana Y, Marin-Jimenez I, Rodriguez-Lago I, Vera I, Martin-Arranz M, Guerra I, et al.
J Clin Med
. 2022 Jan;
11(2).
PMID: 35054116
We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This...
10.
Sanchis-Artero L, Martinez-Blanch J, Manresa-Vera S, Cortes-Castell E, Valls-Gandia M, Iborra M, et al.
Sci Rep
. 2021 May;
11(1):10016.
PMID: 33976272
Intestinal dysbiosis is key in the onset and development of Crohn's disease (CD). We evaluated the microbiota changes in CD patients before and after a six-month anti-TNF treatment, comparing these...